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Abstract 
 
In cardiac muscle, a number of posttranslational protein modifications can alter the function of the 
Ca2+ release channel of the sarcoplasmic reticulum (SR), also known as the ryanodine receptor 
(RyR). During every heartbeat RyRs are actvated by the Ca2+-induced Ca2+ release mechanism 
and contribute a large fraction of the Ca2+ required for contraction. Some of the posttranslational 
modifications of the RyR are known to affect its gating and Ca2+ sensitivity. Presently, research in a 
number of laboratories is focussed on RyR phosphorylation, both by PKA and CaMKII, or on RyR 
modifications caused by reactive oxygen and nitrogen species (ROS / RNS). Both classes of 
posttranslational modifications are thought to play important roles in the physiological regulation of 
channel activity, but are also known to provoke abnormal alterations during various diseases. Only 
recently it was realized that several types of posttranslational modifications are tightly connected 
and form synergistic (or antagonistic) feed-back loops resulting in additive and potentially 
detrimental downstream effects. This review summarizes recent findings on such posttranslational 
modifications, attempts to bridge molecular with cellular findings, and opens a perspective for 
future work trying to understand the ramifications of crosstalk in these multiple signaling pathways. 
Clarifying these complex interactions will be important in the development of novel therapeutic 
approaches, since this may form the foundation for the implementation of multi-pronged treatment 
regimes in the future. 
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1. Introduction 
 
In cardiac muscle, ryanodine receptors (RyRs) serve as Ca2+ release channels of the intracellular 
Ca2+ store, the sarcoplasmic reticulum (SR). Thereby, they provide a large fraction of the Ca2+ 
required to initiate muscle contraction from beat to beat. They are normally activated by a small 
amount of Ca2+ entering into cardiac muscle cells from the extracellular space, via voltage-
dependent Ca2+ channels. This Ca2+-induced Ca2+ release (CICR) from the SR is the mechanism 
which amplifies the Ca2+ signal and governs excitation-contraction (EC) coupling by activation of 
RyRs (for review see [1]). 
Research on the RyR, both on its structure and function, has been carried out over the last 
decades using multiple experimental approaches and techniques to overcome the difficulty of 
examining a channel that is located intracellularly and therefore not easily accessible. This 
includes assays using isolated SR vesicles (e.g. [2,3]), single RyR channels reconstituted into lipid 
bilayers (e.g. [4-9]), permeabilized cardiomyocytes [10,11], but also various biochemical 
techniques (e.g. see [12,13]). Cellular ultrastructural and co-localization information has been 
obtained with immunocytochemistry and electron tomography [14,15] and structure on the 
molecular level has been assessed with cryo-electron microscopy [16,17]. 
Many of these studies have confirmed the potential of RyRs to undergo several of the numerous 
known posttranslational modifications and a number of reports have provided evidence for 
functional consequences resulting from some of these modifications. These data were frequently 
obtained in very artificial experimental systems and under conditions far away from the natural 
environment of the RyRs. Therefore, it often remained unclear whether and how these 
observations on or near the molecular level would translate into intact and living cardiomyocytes 
and into the entire organ or organism [18]. 
Some time ago it became practical to closely examine RyR function in-situ and within its native 
environment, which means inside living cells. This has become possible because of 
groundbreaking developments of technologies to faithfully image subcellular and microdomain 
Ca2+ signals with appropriate spatial and temporal resolution. These developments were 
significantly driven by the chemical synthesis of bright and kinetically fast fluorescent Ca2+ 
indicators [19,20] and the simultaneous advancements of laser-scanning confocal microscopy 
combined with digital image acquisition and processing [21]. 
Since several excellent reviews cover many aspects of RyR posttranslational modifications on the 
biochemical and molecular level [22-30], here we will concentrate on recent findings that have 
been obtained by examining RyR activity and cardiac Ca2+ signaling on the cellular level, where 
the channels can be examined in their native environment. In particular, we will focus on the 
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consequences of a combined impact of several mechanisms and their mutual interactions during 
physiological regulation of RyRs and during the development of cardiac diseases affecting RyR 
function.  
 
2. The ryanodine receptor 
2.1. The RyR macromolecular complex 
In mammals three RyR isoforms are known: the skeletal muscle form RyR1, the cardiac RyR2 and 
the more broadly expressed brain form RyR3. The cardiac RyR2 is a large macromolecular 
complex consisting of a homo-tetramer with 4 subunits comprising a molecular mass of 565 kDa 
each, totaling 2.2 MDa (for review see [31]). This complex is regulated and modulated in numerous 
ways by ions (e.g. Ca2+, Mg2+, H+), by small molecules (e.g. ATP, cADPR) and by proteins (e.g. 
sorcin, calstabin2, junctin, triadin). Important for this review, the macromolecular complex is also 
associated with protein kinases (e.g. protein kinase A (PKA), Ca2+/caldmodulin dependent kinase II 
(CaMKII)) and phosphatases (e.g. phosphatase 1 and 2A). Some of the kinases and phosphatases 
are tethered to the channel and held near their target sites by means of anchoring proteins. On the 
RyR itself, several phosphorylation sites have been identified (see chapter 3). Furthermore, the 
RyR complex comprises several free cysteines that can be subject to reversible oxidative 
modification (see chapter 4). 
 
2.2. The Ca2+ signaling microdomain in the vicinity of the RyRs 
In cardiac muscle, a large fraction of the RyRs are organized in dyads, where the SR membrane 
contains a cluster of 30-250 RyRs [32] and comes in close contact (gap of ~15 nm) with the T-
tubular membrane, which harbors the voltage-dependent L-type Ca2+ channels. Opening of one or 
more L-type channels can activate CICR via several RyRs within a cluster. The tiny SR Ca2+ 
release generated by these few opening channels gives rise to a Ca2+ spark, an elementary Ca2+ 
signaling event, which can be detected and analyzed using confocal imaging of Ca2+ sensitive 
fluorescence indicators (for reviews see [33,34]). During each heart beat, a large number of Ca2+ 
sparks is activated simultaneously, summing up to form the cardiac Ca2+ transient for the activation 
of contraction. Ca2+ sparks and even smaller Ca2+ release events, Ca2+ quarks, can also occur 
spontaneously, for example during diastole [35,36]. Spontaneous Ca2+ sparks and Ca2+ quarks are 
considered to occur accidentally and underlie the SR Ca2+ leak, but they usually cause no harm. 
However, under conditions of SR Ca2+ overload and in circumstances which sensitize the RyRs, 
single Ca2+ sparks can initiate larger Ca2+ signals, such as Ca2+ waves, traveling along the 
myocytes in a saltatory fashion from sarcomere to sarcomere [37-40]. These Ca2+ waves have a 
substantial arrhythmogenic potential, since they are able to initiate Ca2+ activated currents, such as 
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the Na+-Ca2+ exchange current (INCX), which in turn may depolarize the cardiomyocyte and even 
trigger premature action potentials. 
 
2.3. Ca2+ dependent activation and inactivation of the RyRs 
The open probability of RyRs depends steeply on the cytosolic Ca2+ concentration. The increase of 
the RyR open probability subsequent to openings of L-type Ca2+ channels and entry of Ca2+ into 
the dyadic cleft is the main mechanism for activation of CICR during physiological activity. The 
Ca2+ sensitivity of the RyRs in-situ is low enough to ensure independent activation of adjacent Ca2+ 
spark sites, to allow for the regulation of cardiac Ca2+ signals by virtue of local control and 
recruitment of Ca2+ sparks. The Ca2+ sensitivity of the channels for this type of activation is known 
to depend on several modulators as mentioned above (e.g. pH, Mg2+, sorcin etc.), but also on 
several regulatory or disease-associated posttranslational protein modifications (see chapters 3 
and 4). Inactivation of the RyRs and termination of the Ca2+ sparks in-situ is less well understood 
and is the focus of significant ongoing research efforts. The presently favored mechanism is based 
on regulation of the RyR by the Ca2+ concentration inside the SR. Thereby, lowering the SR Ca2+ 
concentration during a spark would make the RyRs insensitive for Ca2+ on the cytosolic side of the 
channels, which causes their deactivation. This is proposed to occur via a retrograde signal 
mediated by allosteric interactions between calsequestrin (acting as the Ca2+ sensor) and junctin 
and/or triadin and the RyR [2,8,41]. This mode of spark termination could be stabilized by a 
reinforcing mechanism that has been proposed recently based on model predictions. The local SR 
depletion and subsequent decay in Ca2+ release flux from the SR during a Ca2+ spark may 
contribute to the self-termination, because of the resulting decline of the dyadic Ca2+ concentration 
[42]. Other proposed mechanisms for spark termination include Ca2+ dependent inactivation of the 
RyRs [43], but this alternative seems to be of rather minor impact since up to 100 µM cytosolic 
Ca2+ no RyR inactivation was observed in permeabilized cardiomyocytes [44]. Another possibility is 
stochastic attrition, where the probabilistic simultaneous closure of all RyRs in one cluster would 
interrupt their mutual activation by CICR within the dyadic cleft [45]. When all channels close, the 
very high dyadic Ca2+ concentration drops to low cytosolic levels within a few milliseconds [46]. 
However, the probability of all channels to be closed simultaneously is very low given the known 
number of RyRs in a cluster, unless their gating is partly coupled [47]. 
The Ca2+ release termination mechanism mediated by lowering of the SR luminal Ca2+ 
concentration and deactivation of the RyRs could also be important under conditions of SR Ca2+ 
overload, the opposite of the depletion during a Ca2+ spark and CICR. By sensitizing the RyRs for 
Ca2+ on the cytosolic side, elevations of intra SR Ca2+ could initiate or facilitate store-overload 
induced Ca2+ release (SOICR) and arrhythmogenic Ca2+ waves [40,48]. 
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2.4. RyR pharmacology 
Several pharmacological compounds change the function of the channel (for review see [49]). 
Here we only briefly summarize some pharmacological approaches which have been used in 
studies of posttranslational RyR modifications. Experimentally, a millimolar concentration of 
caffeine is often applied as an activator, for example to rapidly empty the SR of Ca2+ and to 
estimate SR Ca2+ content. Tetracaine is utilized as a blocker of the RyRs, for example to eliminate 
the diastolic SR Ca2+ leak and estimate its magnitude from the resulting drop of the cytosolic Ca2+ 
concentration [50]. Ryanodine in low concentrations (nM to µM) locks the channel in a very long-
lasting subconductance state, thereby depleting the SR of Ca2+ and eliminating the SR buffer 
function. For this purpose, it is often combined with thapsigargin, an inhibitor of the SR Ca2+ pump 
(SERCA). At high concentrations ryanodine may block the RyR channel. Recently, few drugs 
already accepted as pharmacotherapeutics in humans have been discovered to have beneficial 
off-target effects on the RyRs. These drugs are presently considered for re-purposing, other 
compounds targeting the RyR macromolecular complex are under development [51,52].  
Pharmacological tools are also available to alter mechanisms of posttranslational modifications. 
This includes activators and inhibitors for protein kinases [53], phosphatases and NO synthases 
[54]. Donors and scavengers for NO, reactive nitrogen and oxygen species (RNS and ROS) have 
been applied with some success (e.g. [55]. In general, the specificity of these tools is quite limited, 
with the exception of inhibitory peptides for some of the protein kinases (e.g. PKI for PKA, AIP for 
CaMKII). 
 
3. RyR phosphorylation 
As mentioned above, the mechanism and functional consequences of RyR phosphorylation has 
attracted much recent attention. Interest in this issue was inspired by a report suggesting that PKA 
dependent   “hyperphosphorylation”   of   RyRs   could   occur   during   heart   failure   (HF)   thereby  
aggravating this condition. Hyperphosphorylation was proposed to promote the Ca2+ sensitivity of 
RyRs resulting in elevated open probability. This in turn would cause a substantial diastolic SR 
Ca2+ leak, which could contribute to low SR Ca2+ content, smaller Ca2+ transients and hence weak 
heart beat [12]. Using mainly biochemical and molecular biology approaches, serine 2808 and 
2030 on the RyR have been identified as possible phosphorylation sites for protein kinase A 
(PKA), and serine 2814 for CaMKII. However, the specificity of these sites for the mentioned 
kinases remains a disputed issue [12,56-58] and additional sites are likely to exist [59]. Moreover, 
a fierce controversy revolves around the functional consequence and pathophysiological relevance 
of the phosphorylation at these sites [60,61]. This debate may result from differences in 
experimental approaches, methods and tools, but also from variations of the particular animal and 
disease models.  
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3.1. Phosphorylation by CaMKII 
The pictures which emerges from the literature seems to be more clear for the consequences of 
CaMKII activation which leads to phosphorylation of serine 2814 on the RyR and possibly other 
sites [59,61], among many collateral targets. CaMKII activity seems to produce quite consistent 
functional changes of the RyRs that are reconcilable with the general prediction over a wide range 
of experimental settings and approaches, extending from single channel experiments to cellular 
Ca2+ signaling and a variety of transgenic animals. In single channel experiments the open 
probability of the RyRs was generally found to be increased upon phosphorylation by CaMKII [62] 
(but see [63]). In isolated cardiomyocytes activation of CaMKII was associated with an increase of 
the Ca2+ spark frequency [64]. Transgenic mice overexpressing the cardiac isoform of CaMKII also 
showed elevated Ca2+ spark frequencies, leading to pronounced SR Ca2+ leak, lower SR Ca2+ 
content and a susceptibility for arrhythmias [65,66]. Ablation of CaMKII resulted in a protection of 
the animals from cardiac hypertrophy, possibly mediated by the unavailability of CaMKII signaling 
in the pathways of excitation-transcription coupling [67,68]. To obtain further insight into the 
functional role of serine 2814 on the RyR several mouse models were engineered to specifically 
scrutinize this site. In one animal the serine 2814 was replaced by an alanine, which removes its 
capability to become phosphorylated by CaMKII (S2814A mouse). Hearts of these animals and 
cardiomyocytes isolated from them showed blunted force-frequency relationships [69] and the 
mice were protected from arrhythmias induced by tachypacing after being subjected to transverse 
aortic constriction (TAC) to induce hypertrophy and failure [70]. Conversely, the S2814D RyR, 
where serine is replaced by aspartic acid, mimics constitutive CaMKII dependent RyR 
phosphorylation and increases the open probability of the channels in bilayer experiments. These 
cells showed elevated Ca2+ spark frequencies that could not be further increased by CaMKII 
activation [70] and the mice developed a propensity for arrhythmias and sudden cardiac death 
when stressed with catecholaminergic challenges or tachypacing subsequent to TAC.  
Taken together, these and numerous other studies draw a picture whereby in the short-term 
CaMKII dependent phosphorylation substantially modifies RyR function, cardiac Ca2+ signaling and 
EC-coupling. Overall, these signaling systems seem to become boosted, more active and Ca2+ 
sensitive but less well controlled, from the molecular to the cellular and organ level. Thus, CaMKII 
has been considered as a treatment target for multiple short term and long-term cardiac conditions 
that are associated with disturbances of Ca2+ signaling and CaMKII activation [71-74]. 
 
3.1. Phosphorylation by PKA 
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PKA  dependent  phosphorylation  and  “hyperphosphorylation”  of  the  RyRs at serine 2808 has been 
proposed to dissociate the stabilizing protein calstabin 2 (a.k.a FKPB-12.6) from the 
macromolecular complex, a sequence of events that is suggested to be followed by major 
functional changes of the channels resulting in diastolic Ca2+ leak, SR Ca2+ depletion and weak 
heart beat [12]. Obviously, this mechanism could be very important both for the physiological 
regulation of the channels during stress as well as for their pathophysiological malfunctioning. 
Therefore, it has attracted substantial research efforts from several laboratories. While in general 
phosphorylation of the S2808 site has been confirmed by various labs, specificity for PKA of this 
site, the conditions under which phosphorylation would occur and whether or not this leads to 
calstabin 2 dissociation have remained equivocal [56]. An additional PKA site has been identified 
at serine 2030 [57,75]. On the single channel level, functional changes after PKA-dependent 
phosphorylation have been described some time ago [76,77]. On the cellular level, the 
consequences of PKA-dependent RyR phosphorylation have been more difficult to pinpoint, partly 
because of the complex adjustments of multiple signaling networks downstream the activation of 
PKA in intact or permeabilized cells. Changes of Ca2+ spark parameters indeed were observed 
upon application of cAMP in permeabilized mouse cardiomyocytes, but were entirely attributable to 
the concomitant SERCA stimulation resulting from PLB phosphorylation, as they were not present 
in cells isolated from PLB ablated mice, where SERCA is already maximally stimulated [11]. Two-
photon photolysis of caged Ca2+ to artificially trigger Ca2+ sparks suggested changes of RyR gating 
after   β-adrenergic stimulation, since in resting Guinea pig myocytes larger Ca2+ release events 
were observed despite a decline of SR content [78]. However, when analyzing the frequency of 
spontaneous Ca2+ sparks at rest, this was later found to most likely depend on CaMKII activation 
[79]. 
Because of these difficulties to   dissect   the   consequences   of   β-adrenergic stimulation on RyR 
function, transgenic animals have been engineered specifically targeting the serine 2808 site. 
Several animal models have been created where this serine is replaced by alanine, resulting in 
S2808A channels which can no longer be phosphorylated at this site [58]. Another model are the 
S2808D mice, which have a modification which corresponds to constitutively phosphorylated 
RyRs. Unfortunately, the generation of these animals has not fulfilled the expectation to clarify the 
open issues, as the results published in several reports have again been controversial. Initial 
studies with the S2808A mice showed that the modification was very subtle, did not disturb normal 
cardiac function and the animals had no overt phenotype. However, after myocardial infarction (MI) 
these mice were protected from developing heart failure and from arrhythmias induced by 
phosphodiesterase inhibition [58]. Reconstituted S2808A channels did not show elevated open 
probability after MI, in contrast to those from WT mice. This difference on the molecular level was 
proposed to be the underlying mechanism preventing SR Ca2+ leak, weak heartbeat and the 
susceptibility to arrhythmias in S2808A mice. 
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In a different laboratory, a further S2808A mouse was engineered and these animals were 
subjected to a pressure overload heart failure model after TAC [80]. In this study, no obvious 
cardioprotection was conferred to the animals by ablating the 2808 phosphorylation site. 
Furthermore, no differences between WT and S2808A RyRs were present in the open probability 
and gating kinetics of reconstituted channels. This study then examined Ca2+ signaling and EC-
coupling on the cellular level, including an analysis of Ca2+ sparks and waves. Again, no significant 
differences were observed between the two groups of animals. These observations led the authors 
to conclude that the serine 2808 site only has a limited role in the pathogenesis of heart failure. 
At present it remains unsettled why these apparently similar studies led to essentially opposite 
conclusions. One may speculate that the disease models (i.g. pressure overload versus ischemia / 
inflammatory disease) could result in different outcomes, or that the RyRs of the two engineered 
animals do not operate in a perfectly identical way. Alternatively, some of the resulting functional 
modifications may be rather subtle, and can be compensated by auto-regulatory features of the 
cardiac EC-coupling machinery [81] and are therefore difficult to detect. 
Starting from the latter possibility, a detailed study was carried out to examine SR Ca2+ release 
kinetics,   their   intersarcomeric   synchronization,   and   the   improvement   of   this   parameter   by   β-
adrenergic stimulation when the communication between L-type Ca2+ channels and RyRs was 
challenged [82]. The reasoning for this approach was the notion that these events occur at the very 
interface between the L-type Ca2+ channels and the RyRs and might therefore reveal even subtle 
changes. When this communication was tested by using very small Ca2+ currents as triggers, 
substantial   intersarcomeric   desynchronization   was   observed.   This   was   resynchronized   upon   β-
adrenergic stimulation in the WT [83] but not in the S2808A cells. Furthermore, unlike WT cells, 
Ca2+ wave propagation   was   not   accelerated   upon   β-adrenergic stimulation in S2808A cells. 
Together with the long delays observed in the release synchronization, this suggested the 
possibility of an intra-SR mechanism [40,48], whereby SR Ca2+ loading via SERCA would lead to 
sensitization of the RyR from the luminal side, thereby pushing the channel over the trigger 
threshold. The possibility of an intra-SR mechanism was then confirmed in reconstituted single 
RyR channels. At high SR Ca2+ concentrations, and only under this condition, WT channels indeed 
responded with a significantly larger increase in open probability upon PKA dependent 
phosporylation than S2808A channels. Regarding the ongoing controversy, the main conclusion 
from these studies is that the effects of serine 2808 phosphorylation are present but delicate and 
may be difficult to detect when SR Ca2+ content is not controlled experimentally (e.g. in-vivo, when 
the auto-regulatory adjustments of SR Ca2+ content mentioned above may compensate for small 
changes of RyR open probability).  
Taken together it appears that the mechanisms and consequences of PKA dependent RyR 
phosphorylation are less clear and potentially more subtle than those mediated by CaMKII. 
Whether and how these delicate changes translate into the in-vivo situation is difficult to 
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extrapolate and will require more research. In support for this expectation, a recent cross-breeding 
experiment between dystrophic mdx and S2808A mice indicated that the RyR mutation confers 
significant protection for cardiac disease manifestations and progression of the dystrophic 
cardiomyopathy in these animals (see below) [84]. 
 
4. Redox modification of RyR. 
 
4.1. RyR oxidation by ROS 
Changes of the cellular redox state give rise to another category of posttranslational RyR 
modifications, which do not only have a modulatory function but also play an important role in the 
development  of  various  cardiac  diseases.  The  term  “intracellular  redox  potential”  broadly  describes  
the balance between reduced and oxidized proteins within cells, which in turn is determined by the 
level of generation and buffering of cellular reactive oxygen and reactive nitrogen species 
(ROS/RNS). There are multiple sources of ROS/RNS within the cell. They include but are not 
limited to NADPH oxidase (NOX), xanthine oxidase (XO), mitochondria and nitric oxide synthase 
(NOS). On the other end there are various cellular antioxidant defense components such as 
catalase, superoxide dismutase, thio- and glutaredoxins, glutathione peroxidase, glutathione, 
vitamins A, C and E, etc. Under physiological conditions, the extent of ROS/RNS accumulation is 
finely controlled by these scavenging and reducing mechanisms, and at low concentrations 
ROS/RNS serve as important intracellular messengers. An imbalance between generation of 
ROS/RNS and the efficiency of cellular defense systems can lead to a transient or persistent 
oxidative/nitrosative stress resulting in redox modifications of various cellular proteins, including 
those involved in Ca2+ homeostasis. The RyR is an important example, since it is known to be very 
susceptible to redox modifications. Each cardiac RyR tetramer contains a total of 364 cysteines 
[85].   In   the  presence  of  a  physiological  concentration  of  one  of   the  major  cellular   “redox  buffers”  
glutathione (5 mM) about 84 of these cysteines are free. The sulfhydryl groups of these cysteines 
are subject to reversible cross-linking, S-nitrosylation and S-glutathionylation. Numerous studies of 
RyRs incorporated in lipid bilayers convincingly showed that reversible redox modifications 
significantly affect the activity of RyR channels. Oxidative conditions generally increase the RyR 
open probability, while reducing agents do the opposite (e.g. [85-88]). Therefore, the functional 
consequence of a moderate cellular oxidative/nitrosative stress could be immediate enhancement 
of Ca2+ release from the SR in response to a given physiological trigger. This possibility has been 
supported by experiments with isolated SR vesicles (e.g. [85,89]). The increased Ca2+ sensitivity of 
RyRs and subsequently larger Ca2+ transients could have a positive inotropic effect on the cardiac 
function [90]. However, severe oxidative stress can cause irreversible and sustained activation of 
RyRs [85], increased Ca2+ leak from the SR, decreased SR Ca2+ load and finally a decline of beat-
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to-beat cellular Ca2+ transients with contractile dysfunction. Such conditions are usually associated 
with or even caused by the development of various cardiac abnormalities. Therefore, the role of 
RyR redox modifications in cardiac pathophysiology is currently under intensive investigation in 
multiple laboratories around the world. 
When the experimental gear was shifted from molecular and vesicles towards studies of cells, 
organs and organisms, it became obvious that the findings obtained from isolated RyR channels 
cannot be translated to more complex biological systems without a critical reevaluation. Besides 
the presence of various cellular sources for ROS, redox modification targets multiple intracellular 
sites including major proteins involved in EC coupling and all of them need to be considered in 
order to identify the link between each modification and the resulting changes of RyR function [91]. 
To discriminate between correlative, adaptive and causal posttranlational RyR modifications is 
often a daunting task. 
Cardiac muscle has a substantial NOX activity (for reviews see [92,93]). It has been reported that 
NOX2 is the predominant isoform expressed in T-tubular and SR membranes of mature 
cardiomyocytes. Therefore, it is strategically positioned to modulate the activity of the RyRs. NOX 
is an enzyme that utilizes NADPH to produce superoxide anion. NOX2 was found to be 
overexpressed and/or its activity increased in dystrophic hearts [55,94], in hearts of patients with a 
history of atrial fibrillation [95], and in hearts subjected to tachycardic preconditioning [96]. 
Although the exact mechanisms of NOX activation under these pathological conditions remain 
unclear, it was shown that ROS produced by NOX stimulates SR Ca2+ release via at least two 
pathways: 1) direct oxidation or S-glutathionylation of RyRs or 2) indirectly through CaMKII 
activation [97] followed by phosphorylation of the RyRs. Reducing or ROS scavenging compounds 
could generally mitigate or prevent the consequences of oxidative stress in these experimental 
models. Another widely recognized source of ROS production in cardiac myocytes are 
mitochondria [98,99]. Mitochondria always generate a small amount of ROS through leakage in the 
electron transport chain during respiration. Under some pathophysiological conditions, such as 
ischemia/reperfusion, ROS produced by mitochondria become the main contributors to cellular 
oxidative stress. In this situation mitochondrial Ca2+ overload and subsequently ROS 
overproduction may trigger mitochondrial permeability transition, which in turn boosts ROS 
production via ROS-induced ROS release mechanisms [100,101]. There are also several reports 
indicating upregulation of XO activity in experimental models of heart failure [102]. Furthermore, 
contractile function and myocardial efficiency in HF could be improved by the treatment the 
animals with the xanthine oxidase inhibitor allopurinol [103,104]. Overall, regardless of the source 
of their generation, ROS and subsequent oxidative modifications of RyRs have been directly held 
accountable for augmented stretch-induced Ca2+ responses and hypersensitive EC-coupling in 
dystrophic cardiomyocytes [55,105-108] as well as in impaired Ca2+ signaling in failing [109,110] 
and diabetic hearts [111,112]. 
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4.2. RyR modifications by RNS 
The two major isoforms of NO synthase (NOS) in cardiac myocytes are eNOS and nNOS. They 
have a specific sub-cellular localization and are possibly aimed at different targets in their 
microdomains, due to the short range of NO diffusion. The eNOS isoform is localized in the plasma 
membrane in caveolae through interaction with caveolin-3. In healthy cardiac muscle nNOS is 
mainly located in the SR membrane, linked to the RyRs. In failing or diseased hearts nNOS may 
partly redistribute to the sarcolemma. Normally, the iNOS isoform is not present in significant 
amounts, but this may be different during the development of cardiac diseases. NO produced by 
these enzymes can bind to free thiol groups on various proteins, including RyR, causing S-
nitrosylation and conformational changes. Alternatively, NO can act via the cGMP dependent 
pathway and activated PKG, a protein kinase which is thought to phosphorlyate the RyR at the 
S2814 CaMKII site [59]. This and the presence of many other targets for NO and PKG, most 
notably the L-type Ca2+ channels, make it very challenging to attribute any functional change to a 
specific RyR posttranslational modification in the setting of experiments with intact cells.  
An important role for RyR nitrosylation in cardiac EC-coupling and Ca2+ signaling was suspected 
already some time ago (for review see [90]), when it was found that the stretch-induced 
enhancement of cardiac Ca2+ signals and elevation of Ca2+ spark frequency was blunted in the 
presence of L-NAME, an unspecific inhibitor of all NOS isoforms [113]. The effect of stretch could 
be mimicked by adding the NO donor SNAP, which nearly doubled the Ca2+ spark frequency. 
Additional studies reported that NO could have diverse actions, depending on the preexisting 
extent of β-adrenergic stimulation. NO donors increased the Ca2+ spark frequency in a cGMP 
independent way at low (10 nM) concentrations of ISO, presumably by RyR nitrosylation [114]. At 
1 µM ISO a decrease of the spark frequency was observed, however this was accompanied (or 
caused) by a reduction of the SR Ca2+ content. In nNOS-/- mice, but not in eNOS-/- mice, 
hyponitrosylation of the RyRs was observed, confirming that the structural proximity between 
nNOS and RyR is functionally relevant. Interestingly, these RyRs exhibited more extensive 
oxidative modifications, leading to elevated SR Ca2+ leak [115]. Thus, constitutive RyR S-
nitrosylation in WT animals appears to confer some protection of the channels against more 
severe oxidative modifications. This may be important in various diseases, where changes of the 
nitrosylation have been implied in their pathology, but also in conferring some cardioprotection 
[116]. 
In one study the extent of RyR nitrosylation was quantified in mice with dystrophic cardiomyopathy  
and found to be increased around 4-5 fold [117], while PKA dependent RyR phosphorylation was 
not significantly elevated. This was accompanied by a doubling of the frequency of spontaneous 
Ca2+ sparks and a propensity for arrhythmias. The extent of RyR oxidation and CaMKII-dependent 
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RyR phosphorylation was not assessed directly, but the protective effect of N-acetyl cysteine 
(NAC) suggests an important role of oxidative stress in dystrophic cardiomyopathy, as reported 
earlier ([55,94]. 
The general concept which emerges from these partly controversial studies, although rather 
diffuse, suggests that the reciprocal interactions between RyR modifications resulting from ROS 
and RNS and their functional outcome are very complex and not yet fully understood. While some 
observations suggest quite synergistic actions, in other experimental settings more competitive 
effects between ROS and RNS modifications become apparent. Interactions between ROS and 
RNS are possible in various ways, for example through their tightly connected chemistries (e.g.  
superoxide and NO can combine to form peroxynitrite [118] or by competing for the same thiols on 
the RyR. A further complication in the interpretation of the findings may arise from the finding that 
RyR2 is nitrosylated via S-nitrosoglutathione (GSNO) and not by NO directly [88]. Further, most 
experiments were carried out at ambient oxygen pressure (~150 mmHg), but in the tissue there is 
much less oxygen (~10 mmHg). The degree of oxidation and the function of the cardiac RyR is 
modified by ambient O2. In any case, it seems that the precise balance between ROS and RNS is 
important, and that a NO/ROS disequilibrium can lead to abnormal RyR channel behavior [119].  
 
5. Cross-talk between redox modifications and phosphorylation in disease 
Recently, a number of studies have been carried out in a variety of cardiac disease models, 
focusing on modifications of RyR function and the conceivably underlying posttranslational 
modifications. A common finding in many of these studies was a sequential (i.e. during disease 
development) or simultaneous presence of several posttranslational RyR modifications. While such 
a pattern could result from  parallel but unrelated changes of the involved pathways, it seems more 
plausible that these modifications are not independent from each other. There are numerous 
possibilities for significant cross-talk and synergisms among these signaling pathways, for example 
between ROS, phosphorylation and Ca2+ signals (for reviews see [120,121]. In one scenario, 
boosting the Ca2+ transient by phosphorylating various Ca2+ signaling proteins may elevate 
mitochondrial Ca2+ content, followed by an increased mitochondrial metabolism and ROS 
production [98]. Mitochondrial ROS can further augment the Ca2+ signals by oxidizing multiple Ca2+ 
signaling proteins, as described above, but also by activating CaMKII via redox modification. This 
occurs in addition to the stimulation by the larger Ca2+ transients themselves [97], thereby 
establishing multiple and coupled positive feed-back loops [122]. A multitude of cardiac diseases 
are accompanied by oxidative stress which can initiate similar vicious cycles, just starting from 
another pathomechanism. Examples are congestive heart failure [109], dystrophic cardiomyopathy 
[55], diabetes [112] and ischemia/reperfusion [123]. Since phosphorylation, as well as oxidation 
and elevated Ca2+ concentration will increase the RyR open probability, the CICR mechanism will 
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become very sensitive and unstable. To what extent these multiple changes and the concomitant 
posttranslational RyR modifications exert additive effects and whether they develop rapidly or 
slowly during the development of a disease is not yet established and needs to be investigated in 
the future. However, a number of recent studies are in line with this possibility, which would be 
relevant for future therapeutic strategies. In the presence of synergistic pathomechanisms, multi-
pronged therapies could be designed to target several of these vicious cycles simultaneously. 
Interactions between RyR oxidation and phosphorylation have been studied in dystrophic 
cardiomyopathy, a disease that combines a high degree of oxidative stress and excessive Ca2+ 
signals after mechanical stress, resulting from the lack of the protein dystrophin [55]. In one 
example, a cross-breeding approach has been applied to test for rescue from this disease by 
eliminating not the main pathomechanism, but another step in the vicious cycle [84]. Dystrophic 
mdx mice were crossed with RyR-S2808A mice, which carry RyRs that cannot be phosphorylated 
at this site. Ablation of this phosphorylation site protected these animals, even though not the main 
pathomechanism was targeted, but rather one of the other steps in the positive feed-back loop. 
Unlike mdx mice, these animals did not develop cardiac hypertrophy with fibrosis and showed 
improved cardiac function. Further, they were protected from isoproterenol-induced arrhythmias 
and SR Ca2+ leak. These findings suggest that PKA dependent RyR phosphorylation contributes to 
the abnormal Ca2+ homeostasis in dystrophic cardiomyopathy.  Interestingly, and in apparent 
contrast to these findings, another study was not able to detect significant PKA dependent RyR 
phosphorylation in mdx mice [117]. However, more recent studies suggest that the disease 
phenotype and the pattern of RyR posttranslational modifications change in the course of 
dystrophic cardiomyopathy, and other diseases as well. PKA activation seems to become 
important only at later stages, and is associated with elevated SR Ca2+ leak and reduced Ca2+ 
content [108]. 
 
6. RyR mutations and posttranslational modifications 
Another layer of complexity is added to the intricate mutual interactions of all the posttranslational 
modifications discussed above in patients carrying a mutation of the RyR2 [124,125]. Many of 
these patients are prone to stress-induced arrhythmias, manifesting themselves as 
catecholaminergic polymorphic ventricular tachycardias (CPVTs), potentially leading to sudden 
cardiac death. Cell lines and transgenic animals have been engineered expressing RyRs harboring 
mutations that were identified in families with CPVT patients [126-129]. These animals replicate 
the human disease phenotype and serve as disease models to investigate pathomechanisms 
arising from RyR mutations and to develop therapeutical approaches. In these disease models, 
arrhythmias   could   be   provoked   by   tachypacing   and/or   by   β-adrenergic stimulation. In cellular 
experiments, these cardiomyocytes exhibited elevated Ca2+ spark frequencies, a propensity for 
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diastolic Ca2+ waves with delayed after-depolarizations and reduced wave thresholds. These are 
all signs for disturbed channel gating with a predisposition towards abnormal Ca2+ sensitivity of 
mutated channels (cytosolic or SR luminal). In summary, the phenotypes resulting from RyR 
mutations share many features with the functional consequences of the posttranslational 
modifications discussed above. 
 
7. Conclusion and outlook 
While we start to understand the consequences of various posttranslational RyR modifications on 
the molecular level, we also develop the awareness for the extraordinary complexity of this issue 
on the cellular and organ level. This partly results from the multiple crosstalks and interactions of 
the various signaling pathways and their intertwined positive and negative feed-back loops. A large 
amount of research will thus be required to address the question whether all the regulatory and / or 
pathophysiologically important mechanisms changing RyR function behave in additive, competitive 
or mutually exclusive ways. One example should be mentioned here: It is well established, that 
physical or emotional stress can trigger CPVTs in patients harboring cardiac RyR mutations. 
However, it is so far unknown what exactly triggers these arrhythmias during the stress. Is it 
provoked by additional RyR sensitization originating from PKA or CaMKII dependent RyR 
phosphorylation? Or is it the result of the concomitant stimulation of the SERCA after PLB 
phosphorylation? Or is it the combination of the two possibilities which is particularly detrimental? 
To answer these and many similar questions relevant for other cardiac conditions, it needs to be 
understood in more detail, on the molecular level, how these modifications interact to bring about 
functional change. These findings then need to be integrated into the more complex situation of 
intact cells, organs and organisms. Based on the presently available literature, only partly 
discussed above, one is inclined to predict that such interactions exist and are very important. 
Understanding these interactions will lay the foundation for the development of mechanism based 
therapies, potentially targeting several synergistically acting mechanisms simultaneously.  
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Figure legends: 
Fig. 1. Modulation of the ryanodine receptor (RyR) by Ca2+  and phosphorylation. Ca2+ influx via 
the L-type Ca channel (LTCC) activates the RyR and triggers Ca2+ release from the sarcoplasmic 
reticulum (SR), a process referred to as Ca2+ induced Ca2+ release or CICR, leading to myocyte 
contraction. The levels of free cytosolic Ca2+ are tightly regulated by the SR Ca2+ ATPase (SERCA) 
and the sarcolemmal Na+-Ca2+ exchanger (not indicated). After CICR and contraction, the Ca2+ 
store is refilled by pumping Ca2+ back into the SR thereby re-establishing diastolic Ca2+ levels. The 
sensitivity of RyR toward activating Ca2+ is modulated by phosphorylation. Stimulation of the ß1-
adrenoreceptor (ß-AR) leads to Gs-protein-mediated activation of adenylyl cyclase (AC) and 
further cAMP-dependent activation of PKA. PKA can directly phosphorylate RyR at several 
phosphorylation sites, presumably at S2808, possibly inducing dissociation of calstabin 2, and at 
S2030, but also modulates the LTCC and SERCA function, the latter by phosphorylation by of 
phospholamban (PLB). Increased cytosolic Ca2+ levels activate CaMKII, which directly 
phosphorylates RyR at S2814. Similar to PKA, CaMKII also phosphorylates PLB and the LTCC 
leading to global changes in myocyte Ca2+ homeostasis. 
 
Fig. 2. Redox-modifications of RyRs. Changes in the redox potential of the myocyte have been 
shown to have a serious influence on protein function, especially at the level of the RyR. The main 
sources for the production of reactive oxygen species (ROS) in cardiomyocytes are the 
sarcolemmal NADPH oxidase (NOX), the xanthine oxidase (XO) and the mitochondrial electron 
transport chain (complex I through IV). ROS can glutathionylate free cysteine residues on the RyR 
and also act in an indirect way via CaMKII activation and subsequent RyR phosphorylation. Nitric 
oxide synthases (NOS) are mainly responsible for the production of nitric oxide (NO) and reactive 
nitrogen species (RNS). In cardiomyocytes, sarcolemmal endothelial NOS (eNOS), which co-
localizes with caveolin-3 (Cav3) in caveolae, and RyR-associated neuronal nNOS are primarily 
responsible for the production of NO, causing S-nitrosylation at free thiol groups of the RyR and 
many other proteins. RNS also lead to PKG activation and RyR phosphorylation presumably at 
S2814. Most likely, these mechanisms work synergistically and induce parallel modifications of 
RyR function. 
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